Psychedelics

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Champignon Brands Inc. for violations of §§10 and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange CommissionInvestors who purchased the Company's securities between March 27, 2020 and February 17, 2021, inclusive are encouraged ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Champignon Brands Inc. ("Champignon" or "the Company") (OTC PINK:SHRMF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission

Investors who purchased the Company's securities between March 27, 2020 and February 17, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 9, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Champignon failed to maintain sufficient internal controls over financials. The Company's issued financial statements were false and could not be relied upon, and required restatement. The Company engaged in acquisitions with undisclosed third parties. As a result, the British Columbia Securities Commission would suspend the Company from trading. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Champignon, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/640296/SHAREHOLDER-ACTION-NOTICE-The-Schall-Law-Firm-Reminds-Investors-of-a-Class-Action-Lawsuit-Against-Champignon-Brands-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

News Provided by ACCESSWIRE IA via QuoteMedia

Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to present at the following upcoming May 2022 conferences.

PSYCH Symposium: London 2022

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health

Optimi Health Granted Amendment To Controlled Substances Dealer's Licence

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that a requested Amendment to its Controlled Substances Dealer's Licence has been granted by Health Canada, enabling it to further expand the capacity to produce natural, GMP psilocybin at its Princeton, British Columbia facility, as well as introducing a provision allowing the Company to extract psilocin for use in clinical trials.

Optimi's operational footprint now includes 20,000 square feet of state-of-the-art, technologically advanced aeroponics facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Under the terms of the amendment, the Company is now permitted to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
investor reviewing his stocks

Psychedelics Sector Shifting Gears, Broad Market Forces at Play

Experts believe investor concerns surrounding valuations in the psychedelics market need to be adjusted.

Panelists at a recent Psychedelic Capital monthly event from Microdose discussed a shift in the psychedelic medicine business, and how market trends outside of the industry are at play.

The talk, titled “Market Consolidation: The Next Stage for the Industry?” took place amid an ongoing downturn in value for publicly traded psychedelics companies.

Keep reading...Show less
Nirvana Life Sciences Inc. Announces the Appointment of Jakson Inwentash to the Board of Directors

Nirvana Life Sciences Inc. Announces the Appointment of Jakson Inwentash to the Board of Directors

Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Jakson Inwentash to the Company's Board of Directors.

Mr. Inwentash is a Director and VP Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early-stage companies in various disruptive industries as investment targets. He is also a registered Dealer Representative and has a successful track record of raising capital in industries such as mining, battery recycling, organic food, high performance computing, biotechnology and blockchain.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May 2022.

The management team will host a conference call at 8:00am ET (1:00pm UK) on 10 May. The call can be accessed by dialing (800) 926-7358 from the United States, +1 (212) 231-2914 internationally, and 0800 496 0823 from the UK, followed by the conference ID: 22018578.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

Positive early signals seen in two investigator-initiated studies presented
at the Society of Biological Psychiatry Annual Meeting in New Orleans


News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×